Contact Us
  • Choose License Type

Global Androgen Replacement Therapy Market, By Product Type (Creams/Gels, Patches, Injections, Implants, and Oral Tablets/Capsules/Gums), By Active Ingredient Type (Testosterone, Methyl Testosterone, Testosterone Undecanoate, Testosterone Enanthate, and Testosterone Cypionate), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,736.9 million in 2020 and is expected to exhibit a CAGR of 3.7% over the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

The increasing number of product approvals and launches, adoption of androgen replacement therapy, and mergers and acquisitions by key players are the major factors that are expected to drive growth of the androgen replacement therapy market during the forecast period.

Product approvals by regulatory bodies are expected drive growth of the androgen replacement therapy market during the forecast period. For instance, in October 2018, Antares Pharma announced the U.S. Food and Drug administration (FDA) approval of XYOSTED (testosterone enanthate) injection. XYOSTED is the first FDA approved subcutaneous testosterone enanthate product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable QuickShot auto injector. XYOSTED has been approved in three dosage strengths, 50 mg, 75 mg and 100 mg, and is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

Key players are focused on development and launch of new advanced androgen replacement therapies in the market, which is expected to contribute significantly to the androgen replacement therapy market growth. For instance, in February 2020, Clarus Therapeutics Inc. announced the launch of JATENZO (testosterone undecanoate) capsules, CIII in the U.S market by prescription for treatment of men with testosterone deficiency (hypogonadism). JATENZO is the first and only oral softgel testosterone undecanoate, and the first oral testosterone medicine approved by the U.S. FDA in more than 60 years. JATENZO is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).

The increasing adoption of androgen replacement therapy by hospitals, wellness centers, and specialty centers is expected to accelerate the androgen replacement therapy market growth in the near future. In October 2019, a Texas, U.S. based therapy center, Richardson Pain & Wellness, announced that a wider population in the U.S. patients may enroll themselves in the center’s Testosterone Treatment Therapy program. This program is designed to increase a patient’s testosterone levels or T levels. While the name may sound intimidating, Richardson Pain & Wellness reassures patients that the treatment simply consists of introducing testosterone directly into the subject’s bloodstream.

Browse 35 Market Data Tables and 33 Figures spread through 182 Pages and in-depth TOC on Androgen Replacement Therapy Market, By Product Type (Creams/Gels, Patches, Injections, Implants, and Oral Tablets/Capsules/Gums), By Active Ingredient Type (Testosterone, Methyl Testosterone, Testosterone Undecanoate, Testosterone Enanthate, and Testosterone Cypionate), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Forecast to 2027"

To know the latest trends and insights related to Androgen Replacement Therapy market, click the link below:

https://www.coherentmarketinsights.com/market-insight/androgen-replacement-therapy-market-3787

Several market players are focused on acquisition of commercial rights to expand their product portfolio and gain maximum share of market. For instance, in April 2016, Aytu BioScience, Inc., a specialty pharmaceutical company focused on commercializing novel products in the field of urology, announced the exclusive licensing of its third commercial-stage urology product in just 11 months, with the execution of a long-term, exclusive license agreement with an affiliate of Acerus Pharmaceuticals Corporation for the U.S. commercial rights to Natesto (testosterone) Nasal Gel.  Natesto is the first and only nasal formulation of testosterone approved by the U.S. Food and Drug Administration (FDA) as a replacement therapy for men diagnosed with hypogonadism.

Key Takeaways of the Androgen Replacement Therapy Market:

  • The androgen replacement therapy market is expected to exhibit a CAGR of 3.7% over the forecast period (2020-2027) owing to product approvals and launches by key players.
  • Among product type, the creams/gels segment is expected to hold a major revenue share in 2027 owing to increasing product launches. For instance, in May 2019, Dr Reddy's Laboratories announced that they have launched generic version of AndroGel 1.62 per cent of AbbVie Inc., testosterone gel in the U.S. market which is used in treating adult males with low or no testosterone due to certain medical conditions.
  • Major players operating in the androgen replacement therapy market are AbbVie, Inc., Allergan Plc, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International Plc, Mylan N.V., Novartis International AG, Pfizer, Inc., Clarus Therapeutics, Ferring Holding SA, Perrigo Company Plc, Acerus Pharmaceuticals Corporation, Upsher-Smith Laboratories, LLC, Dr. Reddy's Laboratories, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., and Par Pharmaceutical.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner